A lamotriginre adott klinikai válasz előrejelzése ambulánsan kezelt bipoláris betegeknél: 6 hónapos, multicentrikus, prospektív, obszervációs vizsgálat

Translated title of the contribution: Prediction of response to lamotrigine treatment in bipolar outpatients: A multicentric, 6-month, prospective, observational study

Research output: Contribution to journalArticle

Abstract

In case of a major depressive episode it is crucial to establish whether this is a depressive episode in the course of a bipolar I or bipolar II disorder or a “true” unipolar major depression which is possible through screening for lifetime manic or hypomanic episodes and can be facilitated by the use of the Hypomania Checklist (HCL-32). In cases where (hypo)mania is present in the anamnesis, mood stabilising treatment is warranted even in cases where depressive symptoms predominate the clinical course. However, the association between hypomania in the history and efficacy of mood stabilising lamotrigine treatment has not been previously investigated. In our present study we aimed to analyse clinical and psychosocial characteristics of HCL-32 identified lifetime “upbeat” periods, and to establish if there is an association between baseline-assessed HCL-32 3rd part total scores and remission and relapse rates during 6-month lamotrigine treatment. Our results indicate that baseline HCL-32 group 3rd part scores showed a trend for a moderately strong correlation with remission rates by the 4th visit, and a strong significant correlation was observable by the 5th visit. Overall relapse rate showed a significant strong correlation with baseline HCL-32 3rd part score. Therefore our results indicate that there is an association between baseline-assessed lifetime hypomania scores and higher remission and lower relapse rates during 6-month lamotrigine treatment indicating the efficacy of lamotrigine among patients with hypomania during their illness course.

Original languageHungarian
Pages (from-to)40-45
Number of pages6
JournalNeuropsychopharmacologia Hungarica
Volume20
Issue number2
Publication statusPublished - Jun 1 2018

Fingerprint

Observational Studies
Outpatients
Prospective Studies
Bipolar Disorder
Recurrence
Therapeutics
Depressive Disorder
Checklist
History
Depression
lamotrigine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Clinical Neurology

Cite this

@article{e0da0e92fca04cb08bc2393785ad8967,
title = "A lamotriginre adott klinikai v{\'a}lasz előrejelz{\'e}se ambul{\'a}nsan kezelt bipol{\'a}ris betegekn{\'e}l: 6 h{\'o}napos, multicentrikus, prospekt{\'i}v, obszerv{\'a}ci{\'o}s vizsg{\'a}lat",
abstract = "In case of a major depressive episode it is crucial to establish whether this is a depressive episode in the course of a bipolar I or bipolar II disorder or a “true” unipolar major depression which is possible through screening for lifetime manic or hypomanic episodes and can be facilitated by the use of the Hypomania Checklist (HCL-32). In cases where (hypo)mania is present in the anamnesis, mood stabilising treatment is warranted even in cases where depressive symptoms predominate the clinical course. However, the association between hypomania in the history and efficacy of mood stabilising lamotrigine treatment has not been previously investigated. In our present study we aimed to analyse clinical and psychosocial characteristics of HCL-32 identified lifetime “upbeat” periods, and to establish if there is an association between baseline-assessed HCL-32 3rd part total scores and remission and relapse rates during 6-month lamotrigine treatment. Our results indicate that baseline HCL-32 group 3rd part scores showed a trend for a moderately strong correlation with remission rates by the 4th visit, and a strong significant correlation was observable by the 5th visit. Overall relapse rate showed a significant strong correlation with baseline HCL-32 3rd part score. Therefore our results indicate that there is an association between baseline-assessed lifetime hypomania scores and higher remission and lower relapse rates during 6-month lamotrigine treatment indicating the efficacy of lamotrigine among patients with hypomania during their illness course.",
keywords = "HCL-32, Hypomania, Lamotrigine, Relapse, Remission",
author = "X. Gonda and Z. R{\'i}hmer",
year = "2018",
month = "6",
day = "1",
language = "Hungarian",
volume = "20",
pages = "40--45",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "2",

}

TY - JOUR

T1 - A lamotriginre adott klinikai válasz előrejelzése ambulánsan kezelt bipoláris betegeknél

T2 - 6 hónapos, multicentrikus, prospektív, obszervációs vizsgálat

AU - Gonda, X.

AU - Ríhmer, Z.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - In case of a major depressive episode it is crucial to establish whether this is a depressive episode in the course of a bipolar I or bipolar II disorder or a “true” unipolar major depression which is possible through screening for lifetime manic or hypomanic episodes and can be facilitated by the use of the Hypomania Checklist (HCL-32). In cases where (hypo)mania is present in the anamnesis, mood stabilising treatment is warranted even in cases where depressive symptoms predominate the clinical course. However, the association between hypomania in the history and efficacy of mood stabilising lamotrigine treatment has not been previously investigated. In our present study we aimed to analyse clinical and psychosocial characteristics of HCL-32 identified lifetime “upbeat” periods, and to establish if there is an association between baseline-assessed HCL-32 3rd part total scores and remission and relapse rates during 6-month lamotrigine treatment. Our results indicate that baseline HCL-32 group 3rd part scores showed a trend for a moderately strong correlation with remission rates by the 4th visit, and a strong significant correlation was observable by the 5th visit. Overall relapse rate showed a significant strong correlation with baseline HCL-32 3rd part score. Therefore our results indicate that there is an association between baseline-assessed lifetime hypomania scores and higher remission and lower relapse rates during 6-month lamotrigine treatment indicating the efficacy of lamotrigine among patients with hypomania during their illness course.

AB - In case of a major depressive episode it is crucial to establish whether this is a depressive episode in the course of a bipolar I or bipolar II disorder or a “true” unipolar major depression which is possible through screening for lifetime manic or hypomanic episodes and can be facilitated by the use of the Hypomania Checklist (HCL-32). In cases where (hypo)mania is present in the anamnesis, mood stabilising treatment is warranted even in cases where depressive symptoms predominate the clinical course. However, the association between hypomania in the history and efficacy of mood stabilising lamotrigine treatment has not been previously investigated. In our present study we aimed to analyse clinical and psychosocial characteristics of HCL-32 identified lifetime “upbeat” periods, and to establish if there is an association between baseline-assessed HCL-32 3rd part total scores and remission and relapse rates during 6-month lamotrigine treatment. Our results indicate that baseline HCL-32 group 3rd part scores showed a trend for a moderately strong correlation with remission rates by the 4th visit, and a strong significant correlation was observable by the 5th visit. Overall relapse rate showed a significant strong correlation with baseline HCL-32 3rd part score. Therefore our results indicate that there is an association between baseline-assessed lifetime hypomania scores and higher remission and lower relapse rates during 6-month lamotrigine treatment indicating the efficacy of lamotrigine among patients with hypomania during their illness course.

KW - HCL-32

KW - Hypomania

KW - Lamotrigine

KW - Relapse

KW - Remission

UR - http://www.scopus.com/inward/record.url?scp=85051662646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051662646&partnerID=8YFLogxK

M3 - Article

C2 - 30131450

AN - SCOPUS:85051662646

VL - 20

SP - 40

EP - 45

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 2

ER -